Date posted: 31-Aug-2017
NovaBiotics its participating in this year’s ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance taking place between 6th and 8th September in Boston, Massachusetts.
The conference brings together leading health professionals who are at the forefront of the battle against the urgent global health problem of antimicrobial resistance (AMR).
The NovaBiotics team will present recent data on their novel drug candidates developed from the company's intelligent drug design platforms in response to AMR in bacteria and fungi. Details of the posters can be found below:
Wednesday 6th September /Thursday 7th September - 1545-1645/1530-1630
Cysteamine is a Component of our Innate Immune Defence, Capable of Potentiating Antibiotic Activity Against Priority MDR Pathogens
Wednesday 6th September /Thursday 7th September - 1545-1645/1530-1630
NP108, a broad-specturm antimicrobial polymer in development for the treatment of wound infections
Wednesday 6th September /Thursday 7th September - 1545-1645/1530-1630
NP339 (Novamycin): a novel antifungal peptide solution to the fungal resistance threat
Wednesday 6th September /Thursday 7th September - 1545-1645/1530-1630
NP432, a novel antimicrobial peptide rapidly active against multi-drug resistant bacteria
NovaBiotics Ltd
Silverburn Crescent
Bridge of Don
Aberdeen
AB23 8EW, UK
Tel:+44 (0)1224 711377
Registered Company
No. SC272344
NovaBiotics Inc
One Boston Place,
Suite 2600,
Boston
MA, 02108
Tel:+1 866 259 4527
NovaBiotics
90 Upper George's Street,
Dun Laoghaire,
Co. Dublin,
A96 R8R9
Tel:+353 1 2712605
Registered Company
No. 642058